Plasma Atrial Natriuretic Peptide in Essential Hypertension after Treatment with Irbesartan

التفاصيل البيبلوغرافية
العنوان: Plasma Atrial Natriuretic Peptide in Essential Hypertension after Treatment with Irbesartan
المؤلفون: Olga Gouli, George Dadous, Michalis Karamouzis, Pavlos C. Papadopoulos, Ioannis Kanonidis, P. Kotridis, Basile Kokkas, C.L. Papadopoulos, G. Sakadamis, Chrisoula Karantona, Joshef Karadoumanis
المصدر: Blood Pressure. 11:91-94
بيانات النشر: Informa UK Limited, 2002.
سنة النشر: 2002
مصطلحات موضوعية: Adult, Male, Drug, medicine.medical_specialty, media_common.quotation_subject, medicine.medical_treatment, Tetrazoles, Blood Pressure, Essential hypertension, Receptor, Angiotensin, Type 1, Angiotensin Receptor Antagonists, Irbesartan, Atrial natriuretic peptide, Oral administration, Internal medicine, Internal Medicine, medicine, Humans, Antihypertensive Agents, Aged, media_common, Chemotherapy, business.industry, Biphenyl Compounds, General Medicine, Middle Aged, medicine.disease, Angiotensin II, Endocrinology, Blood pressure, Hypertension, cardiovascular system, Cardiology and Cardiovascular Medicine, business, Atrial Natriuretic Factor, medicine.drug
الوصف: The aim of this study was to evaluate the medium-term effects of the selective AT 1 -blocker irbesartan on atrial natriuretic peptide (ANP) levels in patients with moderate essential hypertension. The drug was given orally in a daily dose of 300 mg for 30 days. Plasma ANP levels increased by 15.7% despite the drop in blood pressure and the slight decrease of atrial and ventricular diameters. These findings indicate that AT 1 -blockers like irbesartan exert part of their antihypertensive action by increasing ANP plasma levels.
تدمد: 1651-1999
0803-7051
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c72166ab421bf1d43a060df92e4c5783Test
https://doi.org/10.1080/08037050211263Test
حقوق: OPEN
رقم الانضمام: edsair.doi.dedup.....c72166ab421bf1d43a060df92e4c5783
قاعدة البيانات: OpenAIRE